ArticleCancer immunology, immunotherapy : CII2009
Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
Article in Cancer immunology, immunotherapy : CII, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 51 citations in OpenAlex.
- Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies.Cancer immunology research · 2024Review
- Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.Journal for immunotherapy of cancer · 2022Article
- Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.International journal of molecular sciences · 2021Review
- CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.Journal for immunotherapy of cancer · 2021Article
- Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review.BMC cancer · 2020Review
- Review
- Emerging Challenges of Preclinical Models of Anti-tumor Immunotherapeutic Strategies Utilizing Vγ9Vδ2 T Cells.Frontiers in immunology · 2020Review
- Organ Biodistribution of Radiolabelled γδ T Cells Following Liposomal Alendronate Administration in Different Mouse Tumour Models.Nanotheranostics · 2020Article
- Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma.Frontiers in immunology · 2019Review
- Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications.Frontiers in oncology · 2019Review
- Investigating in vitro and in vivo αvβ6 integrin receptor-targeting liposomal alendronate for combinatory γδ T cell immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
- Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis.International journal of clinical oncology · 2017Article
- In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.Journal of controlled release : official journal of the Controlled Release Society · 2016Article
- The effect of activated Mϕ1 on γδT cell-mediated killing of gastric cancer cellsOncology letters · 2016Article
- Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy.Oncoimmunology · 2015Review
- γδ T Cell Immunotherapy-A Review.Pharmaceuticals (Basel, Switzerland) · 2015Review
- Gamma Delta T-lymphocytes in Hepatitis C and Chronic Liver Disease.Frontiers in immunology · 2014Review
- Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma.International journal of clinical oncology · 2013Article
- Anti-metastatic potential of human Vδ1(+) γδ T cells in an orthotopic mouse xenograft model of colon carcinoma.Cancer immunology, immunotherapy : CII · 2013Article
- What lessons can be learned from γδ T cell-based cancer immunotherapy trials?Cellular & molecular immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSuperficial bladder cancers are usually managed with transurethral resection followed by the intravesical administration of Bacillus Calmette-Guerin which requires major histocompatibility complex (MHC) class I expression on cancer cells. Since cancer cells often loose MHC expression, a novel immunotherapy such as MHC-unrestricted gammadelta T cell therapy is desired.
objectiveTo clarify the relationship between the expression of MHC class I and clinicopathological features in bladder cancer patients, and investigate the effects of the administration of intravesical gammadelta T cells on bladder cancer.
methodsSamples from 123 patients who had undergone either transurethral resection or radical cystectomies were examined for MHC expression and the relationship between this and the clinicopathological features was analyzed statistically. The in vitro and in vivo effects of gammadelta T cells expanded by zoledronic acid (ZOL) against several types of cancer cell line and an orthotopic bladder cancer murine model which was pretreated with ZOL were investigated.
resultsMHC-diminished superficial bladder cancer was significantly more progressive than MHC-conservative bladder cancer (P = 0.047). In addition, there was a significant association between diminished MHC expression and poor disease free survival (P = 0.041) and overall survival (P = 0.018) after radical cystectomy. In vitro, all of the cell lines pretreated with 5-microM ZOL showed a marked increase in sensitivity to lysis by gammadelta T cells. Moreover, intravesical administration of gammadelta T cells with 5-microM ZOL significantly demonstrated antitumor activity against bladder cancer cells in the orthotopic murine model (P < 0.001), resulting in prolonged survival.
conclusionThe present murine model provides a potentially interesting option to develop immunotherapy using gammadelta T cells for bladder cancer in human.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.